A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine

被引：9

作者：

Hiyoshi M. ^{[1
]}

Nanashima A. ^{[1
]}

Wada T. ^{[1
]}

Tsuchimochi Y. ^{[1
]}

Hamada T. ^{[1
]}

Yano K. ^{[1
]}

Imamura N. ^{[1
]}

Fujii Y. ^{[1
]}

机构：

[1] Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, 5200 Kihara, Kiyotake, Miyazaki

来源：

Clinical Journal of Gastroenterology | 2017年 / 10卷 / 6期

关键词：

Conversion surgery; Curative resection; Gemcitabine; Locally advanced pancreatic cancer; Nab-paclitaxel;

D O I：

10.1007/s12328-017-0793-5

中图分类号：

学科分类号：

摘要：

Pancreatic cancer patients have a poor prognosis because of a low rate of resection that results from distant metastases or local advancement. We report a successful case of unresectable locally advanced pancreatic cancer in a patient who was curatively resected after combination therapy with nab-paclitaxel (nab-PTX) and gemcitabine (GEM). A 61-year-old man was referred for treatment of a 45-mm pancreatic tail tumor involving the celiac axis, common hepatic artery, and splenic artery that appeared as an abnormal soft-density mass on imaging. This patient’s tumor was defined as unresectable due to local advancement, and, therefore, the powerful combined chemotherapy regimen of nab-PTX with GEM was initiated to allow for possible resection later. After three cycles of chemotherapy, a CT scan revealed that the soft-density mass around the celiac axis and common hepatic artery had dramatically disappeared, and the tumor was then determined to be a resectable lesion. Thus, distal pancreatectomy with en bloc celiac axis resection was performed and curability was achieved. There has been no tumor recurrence or distant metastasis at more than 12 months after surgery, and the patient remains alive at 17 months after initial chemotherapy. © 2017, Japanese Society of Gastroenterology.

引用

页码：551 / 557

页数：6

共 31 条

[1]

Hidalgo M., Cascinu S., Kleeff J., Et al., Addressing the challenges of pancreatic cancer: future directions for improving outcomes, Pancreatology, 15, pp. 8-18, (2015)

[2]

Vincent A., Herman J., Schulick R., Et al., Pancreatic cancer, Lancet, 378, pp. 607-620, (2011)

[3]

Ansari D., Bauden M., Bergstrom S., Et al., Relationship between tumor size and outcome in pancreatic ductal adenocarcinoma, Br J Surg, 104, pp. 600-607, (2017)

[4]

Ariake K., Motoi F., Mizuma M., Et al., Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report, Surg Case Rep, 3, (2017)

[5]

Pompa T.A., Morano W.F., Jeurkar C., Et al., Complete response after treatment with neoadjuvant chemoradiation with prolonged chemotherapy for locally advanced, unresectable adenocarcinoma of the pancreas, Case Rep Oncol Med, 2017, (2017)

[6]

Kunzmann V., Herrmann K., Bleumel C., Et al., Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer, Case Rep Oncol, 7, pp. 648-655, (2014)

[7]

Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. NIH publication #09-7473, Published May, 2009, v4.03: June 14, 2010, (2009)

[8]

Eisenhauer E.A., Therasse P., Bogaerts J., Et al., New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1), Eur J Cancer, 45, pp. 228-247, (2009)

[9]

Kondo S., Katoh H., Shimizu T., Et al., Preoperative embolization of the common hepatic artery in preparation for radical pancreatectomy for pancreas body cancer, Hepatogastroenterology, 47, pp. 1447-1449, (2000)

[10]

Hirano S., Kondo S., Hara T., Et al., Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results, Ann Surg, 246, pp. 46-51, (2007)

← 1 2 3 4 →